echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Chem: To achieve deeper tumor photodynamic therapy, Zhejiang University Deng Renren/Zhou Min team develops new photosensitization technology

    Chem: To achieve deeper tumor photodynamic therapy, Zhejiang University Deng Renren/Zhou Min team develops new photosensitization technology

    • Last Update: 2021-04-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The photosensitization reaction that produces reactive oxygen species (ROS) is crucial in the fields of energy conversion, organic waste decomposition, and photodynamic therapy.

    Near-infrared excitation can provide a deeper penetration depth and can penetrate various media (such as wastewater and biological tissues), so the use of near-infrared (NIR) light to achieve photosensitization has good application prospects.

    However, traditional near-infrared photosensitization methods have problems such as low conversion efficiency and difficulty in molecular design.

    Recently, Deng Renren’s team from the School of Materials Science and Engineering of Zhejiang University and Zhou Min’s team from the Institute of Translational Medicine published a study titled: Near-infrared photosensitization via direct triplet energy transfer from lanthanide nanoparticles in the Cell’s Chem journal (IF=19.
    735) paper.

    The research developed a simple lanthanide-triple state sensitization method, coupling an organic photosensitizer to lanthanide nanoparticles to achieve high-performance near-infrared photosensitization.

    This method can efficiently produce reactive oxygen species under ultra-low near-infrared radiation, and has good application value in the fields of tumors and infectious diseases.

    It is worth noting that, compared with the photosensitizers used in traditional photodynamic therapy (compared with more than 40 clinical and scientific photosensitizers), this photodynamic therapy drug has a very significant depth of disease tissue and treatment efficiency.
    improve.

    The molecular triplet exciton state can transfer energy to the lanthanide ions through uniform efficiency, and realize the emission of dark triplet excitons (Figure 1).

    Figure 1.
    Triplet excitation of lanthanide nanocrystal coupling.
    In order to verify the effect of energy coupling on triplet state transfer, Zhou Min’s team studied lanthanide nanocrystals and a series of porphyrin and phthalocyanine derivatives with different triplet energies (PpIX).
    , TCPP, Ce6 and ZnPcS) when combined with photosensitivity.

    The study found that under 808 nm light, only TCPP (T1=1.
    43 eV9), Ce6 (T1=1.
    14 eV) and znpc (T1=1.
    13 eV9) can be effectively sensitized by NaGdF4:Nd nanocrystals (Figure 2).

    Figure 2.
    The near-infrared photosensitized NaGdF4:Nd of lanthanide inorganic nanocrystals coupled with porphyrin and phthalocyanine derivatives can generate more ROS in cells and achieve enhanced photodynamic (PDT) therapy.

    The nanoconjugate modified with folic acid (FA) can achieve specific targeted therapy of SKOV3 deep tumors under low-power density 808 nm laser irradiation.

    Compared with the traditional singlet-triple state PDT method, the lanthanide-triple state sensitization method has deeper tumor penetration and stronger anti-tumor effect (Figure 3).

    Figure 3.
    Nanoconjugates for targeted photodynamic therapy in vitro and in vivo.
    Lanthanide inorganic nanocrystals directly sensitize the triplet excitons of the photosensitizer, which can bypass the crossover process between systems.

    By minimizing the loss of photon energy in the process of activating sensitizer molecules, this method can realize a high-performance near-infrared photosensitive system that works with ultra-low radiation energy, greatly improving the efficacy of deep tissue ablation and cancer treatment, and is a new type of photodynamics.
    The treatment provides new methods and clinical treatment feasibility.

    Zhejiang University doctoral student Zheng Bingzhu, doctoral student Zhong Danni, master student Xie Tingting, and master student Zhou Jian are the co-first authors of this article.

    Researcher Zhou Min from the Institute of Translational Medicine and Professor Deng Renren from the School of Materials Science and Engineering are the corresponding authors of the paper.

    The research work has been funded by the National Key Research and Development Program, the National Natural Science Foundation of China, and the Zhejiang Natural Science Foundation.

    Link to the paper: Open for reprint 
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.